Allucent

Allucent is a specialized, global Clinical Research Organization (CRO) purpose-built to serve the unique, fast-paced needs of small and mid-sized biotechnology and pharmaceutical companies. Formed through the strategic merger of legacy research firms like CATO SMS and Pharm-Olam, the company provides end-to-end clinical trial support to help innovators bring breakthrough therapies to market faster. Under the hood, Allucent manages the incredibly complex lifecycle of drug development—from clinical trial design, decentralized trial execution, and patient recruitment, to regulatory consulting, clinical pharmacology, and biometrics. Their primary target audience consists of emerging biotech startups that possess revolutionary scientific ideas but lack the massive internal infrastructure of "big pharma." What sets Allucent apart in the highly regulated CRO industry is its highly customized, agile approach; they provide smaller innovators with direct access to senior-level scientists and regulatory experts, ensuring that critical, life-saving clinical programs receive the dedicated attention required to successfully navigate global drug approval pipelines.